Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials

被引：11

作者：

Keshavarz, Khosro ^{[1
]}

Lotfi, Farhad ^{[1
]}

Sanati, Ehsan ^{[2
]}

Salesi, Mahmood ^{[3
]}

Hashemi-Meshkini, Amir ^{[2
]}

Jafari, Mojtaba ^{[1
]}

Mojahedian, Mohammad M. ^{[2
]}

Najafi, Behzad ^{[4
]}

Nikfar, Shekoufeh ^{[5
,6
]}

机构：

[1] Shiraz Univ Med Sci, Sch Management & Informat Sci, Dept Hlth Econ, Hlth Human Resources Res Ctr, Shiraz, Iran

[2] Univ Tehran Med Sci, Dept Pharmacoecon & Pharmaceut Adm, Fac Pharm, Tehran, Iran

[3] Baqiyatallah Univ Med Sci, Atherosclerosis Res Ctr, Tehran, Iran

[4] Tabriz Univ Med Sci, Sch Management & Med Informat, Dept Hlth Serv Management, Iranian Ctr Excellence Hlth Management, Tabriz, Iran

[5] Univ Tehran Med Sci, Fac Pharm, Dept Pharmacoecon & Pharmaceut Adm, Tehran, Iran

[6] Univ Tehran Med Sci, Evidence Based Med Grp, Pharmaceut Sci Res Ctr, Tehran, Iran

来源：

DARU-JOURNAL OF PHARMACEUTICAL SCIENCES | 2017年 / 25卷

关键词：

Linagliptin; Type 2 diabetes mellitus; Sitagliptin; Network meta-analysis; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ONGOING METFORMIN THERAPY; INITIAL COMBINATION THERAPY; DRUG-NAIVE PATIENTS; DOUBLE-BLIND; GLYCEMIC CONTROL; DISEASE PREVALENCE; JAPANESE PATIENTS; ELDERLY-PATIENTS; DPP-4; INHIBITOR;

D O I：

10.1186/s40199-017-0189-6

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Diabetes is one of the most common chronic and costly diseases worldwide and type 2 diabetes is the most common type which accounts for about 90% of cases with diabetes. New medication-therapy regimens such as those containing linagliptin alone or in combination with other medications (within the category of DDP-4 inhibitors) must be evaluated in terms of efficacy and compared with other currently used drugs and then enter the medication list of the country. Hence, this study aimed to compare the clinical efficacy of the two drugs, i.e. linagliptin and sitagliptin, in patients with type 2 diabetes. Methods: A systematic review was conducted to identify all clinical trials published by 2015 which compared the two drugs in patients with type 2 diabetes. Using keywords such as "linagliptin", "type 2 diabetes mellitus", "sitagliptin" and related combinations, we searched databases including Scopus, PubMed, and Web of Science. The quality of the selected studies was evaluated using the Jadad score. Considering primary and secondary outcomes extracted from the reviewed studies, a network meta-analysis was used to conduct a systematic comparison between the two studied drugs. Results: This network meta-analysis included 32 studies (Linagliptin vs PLB: n = 8, Sitagliptin vs PLB: n = 13, Linagliptin + MET vs PLB + MET: n = 4, and Sitagliptin + MET vs PLB + MET: n = 7) and a total of 13,747 patients. The results showed no significant difference between linagliptin and sitagliptin in terms of key efficacy and safety outcomes such as HbA1c changes from baseline, body weight change from baseline, percentage of patients achieving HbA1c <7, and percentage of patients experiencing hypoglycemic events (p > 0.05). The results showed that the efficacy of the two drug regimens was the same. Conclusions: Based on the results, there was no significant difference between the two drugs, i.e. linagliptin and sitagliptin, in terms of efficacy; in other words, the efficacy of the two drugs was the same. Therefore, the use of these two drugs depends on their availability and cost.

引用

页数：11

共 56 条

[1] Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus [J].